Navigation Links
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
Date:10/8/2007

r of Gastroenterology and Endoscopy at John Radcliffe Hospital, Oxford and the lead investigator in Europe.

Ocera also recently announced the initiation of Phase 2 trials with AST-120 in Irritable Bowel Syndrome and Hepatic Encephalopathy. AST-120 is an oral agent known to adsorb bile acids, toxins and mediators of inflammation from the gastrointestinal tract with the potential to address multiple gastrointestinal diseases. Ocera in-licensed AST-120 from Kureha Corporation based in Tokyo, Japan. AST-120 is not absorbed in the gut and is marketed in Japan and Korea for chronic kidney disease, where it has been used in more than 200,000 patients.

About FHAST1

Fistula Healing With AST-120 is a double-blind, placebo controlled pivotal Phase 3 trial evaluating the efficacy and safety of AST-120 for eight weeks in 240 patients. The primary efficacy endpoint of the study is the number of patients with at least a 50 percent reduction in the number of draining fistulas at both week four and week eight compared to the baseline. Secondary endpoints include changes in Crohn's Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI), two markers of disease severity and quality of life. Ocera expects initial data to be released in the first quarter of 2008. Patients treated in the FHAST1 study who respond to therapy are followed up for six months. In addition, patients who did not respond to the initial regimen have the opportunity to switch to the alternate treatment, ensuring that patients randomized to placebo who fail therapy can have access to AST-120.

For information on Ocera Therapeutics sponsored clinical trials, please visit http://www.clinicaltrials.gov. Key word: AST-120.

About Crohn's Disease

Crohn's disease is a chronic disorder that causes inflammation of the digestive tract that most commonly affects the small intestine and/or the colon. Some patients may d
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. LANI completes Phase I in Japan and to commence Phase I in UK
7. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., FREMONT,Calif.,Nov.24/PRNewswire-FirstCall/--Ver...mpanyfileditsPlanofReorganizationandDisclosureStat...ruptcyCourtfortheDistrictofDelaware.Ahearingtocons...eduledforDecember8,2009,withthehearingontheconfirm...PlancallsfortheCompanytopayallclaimsinfull.ThePlan...
(Date:11/24/2009)..., WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNewswire/-...oodandDrugAdministration(FDA)hasacceptedforreviewE...pt®(donepezilHClextendedrelease)tabletsforthe...Thisnewhigherdoseformulationcontains23mgofdonepezi...verysystemthatallowsforgradualreleaseofthedrug.The...
(Date:11/24/2009)..., PLEASANTON,Calif.,Nov.24/PRNewswire-FirstCall/--...evice-basedmechanicalcirculatorysupporttherapiesto...twillbeparticipatinginthe21stAnnualPiperJaffrayHea....Smith,executivevicepresidentandchieffinancialoffi...0a.m.,EasternStandardTime(5:30a.m.,PacificStandard...
Breaking Medicine Technology:Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Living in U S May Raise Hispanics Cancer Risk 53835 1Living in U S May Raise Hispanics Cancer Risk 53835 2Living in U S May Raise Hispanics Cancer Risk 53835 3Oncothyreon announces webcast of second quarter 2009 financial results conference call 13414 1China Sky One Medical Inc Appoints New Independent Director 13412 1China Sky One Medical Inc Appoints New Independent Director 13412 2China Sky One Medical Inc Appoints New Independent Director 13412 3
... LEIDEN, The Netherlands, January 13 ProFibrix B...rcial license agreement with Crucell,N.V. (Euronex...6(R), a unique,human protein production platform. ...ture recombinant human fibrinogen at levels that s...new products. Fibrinogen is at the,heart of all Pr...
...SHINGTON, Jan. 12 American Life League,s historic...st pioneers in adult stem cell research and regene...com/cgi-bin/prnh/20081105/DC44231LOGO ) , , Dr. ...ogy and President of Sound Choice Pharmaceutical I...ce in scientific research, discovery, production a...
Other Medicine Technology:ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell 2Stem Cell Pioneer to Speak to A.L.L. Personhood Conference 2
(Date:11/25/2009)....,Nov.25/PRNewswire-USNewswire/--AnarticlebyJanetW...tionandResearch,titled"ADifficultBalance-PainManag...9issueofTheNewEnglandJournalofMedicine. ,, (Log...ALOGO ) ,, Inthearticle,WoodcockdiscussesFDAeff...orthosewhoneeditandmanagingtherisksposedbyvariousa...
(Date:11/25/2009)...Endorsements,Business,andPressJoinEfforttoEducate ...--Onceagain,theNationalBipolarFoundationandtheMedi..."Safe,tilStable"program,whichisnowbeingwidelyaccep...r.Today,theNationalBipolarFoundationreceivedaprocl...romtheLt.GovernorofLouisianaMitchLandrieu.TheNatio...
(Date:11/25/2009)...ery that grew out of a collaboration between UCLA ...ope to the nearly 10 million Americans who suffer ...wn as hardening of the arteries, peripheral arteri...m in which narrowed arteries reduce blood flow to ...for vascular disease, heart attack and stroke, and...
(Date:11/25/2009)... to fight rheumatoid arthritis, could help newly d...ESDAY, Nov. 25 (HealthDay News) -- A drug commonly...id arthritis now also shows some promise in helpin..., The drug, rituximab (Rituxan), helped patients...ough the disease had destroyed some of their pancr...
(Date:11/25/2009)... by neurological symptoms, study finds , ...gical side effects are among the potential problem...r who were treated with cisplatin-based chemothera... 1,409 Norwegian men treated for unilateral testic... a follow-up survey conducted from 1998 to 2002. ,...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...udy, marijuana enhances the efficacy of drug treat... affected by this fatal viral infection. The findi...offer medical benefits in certain situations. ...eme fatigue, nausea, muscle aches, loss of appetit...
... cancer from Canada states that young women betwee...e of cancer than young men. // The national r... the Public Health Agency of Canada on people aged...ries, with projections to 2005. Dr. Loraine...
...half of hundreds of HIV-positive Libyan children h...on dinars ($11.6 million) in compensation. // ...sday, which was retrying six foreign medics who ha... a Palestinian doctor that had begun in May that t...
...loped that would reduce the bio-terrorism threat o... Biomedical researchers at the University of Tex...ed to start the initial step in the development of... the specific structure of a protein that the viru...
...dren are not checked properly for their safety and...ical Center researchers. // The drugs that are bei...ants, antiseizure medications and sedatives. ...istration (FDA) may extend the period of time that...
...mber of HIV infected individuals, India plans to a...e in the country to // teach others about safe sex...could be weavers, or agricultural laborers or just...istribution of condoms, and messages on radio and ...
Other Medicine News:Health News:Cancer Rates Falls In Younger Men But Stable In Young Women 2Health News:Libyan Lawyers For The HIV-positive Children Seek 15million Dinars As Compensation 2Health News:A New drug Developed To Fight The Bio-Terrorism Threat Of VEE Virus 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 3
Nagashima Rigid Fiber Optic Antroscope SFA-II-W
Kaye Skin Hook
Joseph Single Hook
Cottle Single Hook
Medicine Products: